二甲双胍联合来曲唑治疗多囊卵巢综合征排卵障碍性不孕的临床疗效研究

目的分析二甲双胍联合来曲唑治疗多囊卵巢综合征(PCOS)排卵障碍性不孕的效果。方法 80例PCOS排卵障碍性不孕患者作为研究对象,按照随机数字表法分为对照组和观察组,各40例。对照组采用来曲唑治疗,观察组采用二甲双胍联合来曲唑治疗。比较两组患者治疗效果、不良反应发生情况及治疗前后黄体生成素(LH)、睾酮(T)及雌二醇(E2)水平。结果观察组治疗总有效率为95.00%,显著高于对照组的77.50%,差异有统计学意义(P<0.05)。治疗后,观察组LH(7.04±0.51)U/L、T(1.54±0.24)nmol/L及E2(134.53±1.56)pmol/L均低于对照组的(8.85±0.86)U/L、(2.72±0.33)nmol/L、(142.85±2.62)pmol/L,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论对PCOS排卵障碍性不孕患者采用二甲双胍联合来曲唑治疗,其治疗效果更佳。

Study the clinical efficacy of metformin combined with letrozole in the treatment of ovulation dysfunction infertility due to polycystic ovary syndrome

Objective To analyze the effect of metformin combined with letrozole in the treatment of ovulation dysfunction infertility due to polycystic ovary syndrome(PCOS). Methods A total of 80 patients with ovulation dysfunction infertility due to PCOS as study subjects were divided into control group and observation group by random number table method, with 40 cases in each group. The control group was treated by letrozole, and the observation group was treated by metformin combined with letrozole. The therapeutic effect, occurrence of adverse reactions, and luteinizing hormone(LH), testosterone(T) and estradiol(E2) levels before and after treatment were compared between the two groups. Results The total effective rate of treatment was 95.00% in the observation group, which was significantly higher than 77.50% in the control group, and the difference was statistically significant(P<0.05). After treatment, the level of LH(7.04±0.51) U/L, T(1.54± 0.24) nmol/L and E2(134.53±1.56) pmol/L in the observation group were lower than(8.85±0.86) U/L,(2.72±0.33) nmol/L and(142.85±2.62)pmol/L in the control group, and their difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05). Conclusion Metformin combined with letrozole shows better therapeutic effect in the treatment of patients with ovulation dysfunction infertility due to polycystic ovary syndrome.